Release date: 2017-08-21 John McCain (Source STAT) Who is McCain? Prior to this, Xiaobian did not know him until he had glioblastoma (GBM). He once fought with Obama for the presidency, is now a US senator, and is also a US political star. So the two US presidents immediately responded after learning about the matter. Obama Twitter posted (image source twitter) Former President Barack Obama issued a message: "John McCain is an American hero and the most brave fighter I know. Cancer doesn't know who it is facing. Give it a taste, John." President Trump also expressed his blessing: "Secretary McCain is always a fighter. Melania and I send our greetings and blessings to Senator McCain and his wife Cindy and all his family. I hope he Recover as soon as possible." Glioblastoma (GBM) is known to be the most malignant brain cancer in gliomas. The American Cancer Society estimates that patients with glioblastoma over 55 years of age have a 5-year survival rate of only 4%. Even with the most aggressive treatment, the median survival was still less than 15 months. (Note: McCain is 81 years old) Therefore, researchers have been exploring new treatments. Recently, two papers published in the journals Neuro-oncology and International Journal of Oncology show that researchers at the University of Florida use CAR-T therapy targeting CD70 in the course of human cancer cells and animal models. A strong anti-tumor response has been produced. Huang Jianping (picture source ufl.edu) As the first author of the two studies, Dr. Huang Jianping of the University of Florida neurosurgery said: "We believe that this discovery shows the great potential of immunotherapy and has new hopes for the treatment of glioblastoma." Researchers at the University of Florida (UF) demonstrated a group of mouse models treated with CAR-T cells after demonstrating that CD70-specific CAR-T cells specifically target and kill tumors in mouse and human cells. The success was also achieved in China, 38% of the mice were completely eliminated, and the survival of other mice was significantly prolonged. In glioma models, mCAR-T cells induce complete response and prolong survival (Source IJC) At the same time, the researchers said that no side effects were found in the experiment, indicating that the treatment is both effective and safe. Dr. Duane Mitchell, co-author of the two papers, said: "Because of the fatal brain cancer of glioblastoma, a new treatment option is urgently needed, so the new CAR-T cell therapy for CD70-positive brain tumors is also Florida. The University (UF) Brain Tumor Immunotherapy Program places high priority on priorities. CD70 gene expression was negatively correlated with overall survival in patients with primary glioma (Source: IJC) The ultimate goal of the study is of course to translate the therapy into clinical applications, so next, Dr. Huang Jianping will lead his team to study the effects of CAR-T treatment combined with other anti-tumor therapies. She said preliminary data from the mouse model showed that local radiation can improve the homing and anti-tumor activity of CAR-T cells. Dr. Huang noted that approximately 35% of newly diagnosed glioblastoma patients and a higher percentage of patients with recurrent tumors carry CD70. Therefore, targeted immunotherapy with CD70 as a target will inevitably become a revolutionary breakthrough in the field of glioma treatment in the future. Prior to this, the medical doctor also reported other advances in the treatment of glioblastoma. Donald M. O'Rourke (Image by Penn Medicine) On July 20, 2017, the University of Pennsylvania and Novartis jointly developed a CAR-T therapy targeting glioblastoma (GBM) targeting EGFRvIII, in a recent clinical trial led by Dr. Donald M. O'Rourke. (NCT02209376), successfully crossed the blood-brain barrier to reach brain tumors, and also showed the safety of the therapy. (Approximately 30% of GBM is highly expressed in EGFRVIII, and EGFRvIII expression is thought to be associated with poor prognosis) Sidi Chen (Source yale.edu) On August 14, 2017, Professor Sidi Chen from the Institute of Systems Biology of Yale University, with the help of Professor Zhang Feng, successfully identified key mutations in glioblastoma through CRISPR technology. The relevant research results were published in the famous international journal Nature Neuroscience. To further demonstrate whether these genetic mutations affect the treatment of gliomas, the researchers conducted further research. The results showed that if a patient with glioma has a Zc3h13 or Pten gene mutation, it will develop resistance to chemotherapy. Based on the results of this study, it is possible to know which treatments are suitable for which type of patients, and take a big step toward individualized cancer therapy. In summary, we have seen new breakthroughs in new therapies for glioblastoma, and also bring hope for survival to patients with brain tumors. Here, we look forward to the successful progress of subsequent clinical trials. About Dr. Huang Jianping Dr. Huang is a member of the University of Florida's Evelyn F. and William L. McKnight Brain Research Institute. He has worked with researchers from the National Cancer Research Institute (NCI) and Harbin Medical University. It is funded by the American Cancer Society, the Wells Foundation, and the Ministry of Science and Technology of the People's Republic of China. Reference source DOI: 10.1002/ijc.30830 DOI: 10.1093/neuonc/nox116 http:// Source: Medical Maike (WeChat emedclub_com) Shandong Longze Mechanical Equipment Co.,Ltd , https://www.pelletmachinefactory.com